Low levels of the vascular endothelial growth factor in CSF from early ALS patients.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 15184633.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Deletion of the hypoxia-response element in the vascular endothelial growth factor (VEGF) promoter causes motor neuron degeneration in a mouse model. "At-risk" haplotypes with low circulating VEGF levels have been demonstrated in humans. Here the authors report low VEGF levels in the CSF of ALS patients during their first year of the disease, independently of VEGF promoter polymorphism. This finding early in ALS patients suggests a possible role for VEGF gene regulation in the pathogenesis of ALS.
Medical subject headings
- Amyotrophic Lateral Sclerosis
- Vascular Endothelial Growth Factor A